Children’s Ward & Children’s Community Nursing Team: Administration of Goserelin Implant (Zoladex®) and Leuprorelin Acetate Depot Injection (Prostap®) Clinical Procedure Policy
1 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015
Policy : Children’s Ward & Children’s Community Nursing Team: Administration of Goserelin Implant (Zoladex®) and Leuprorelin Acetate Depot Injection (Prostap®) Clinical Procedure Policy Executive Summary Goserelin and Leuprorelin are types of hormone therapy drug called and associated lutenizing hormone releasing hormone analogue (LHRHa). Goserelin is documents: also known as Zoladex® and shall be referred to as such within this policy whilst Leuprorelin is also known as Prostap® SR DCS and will be referred to as such within this policy. Both work by interrupting the cycle of hormone production in the body, stopping production of testosterone in men and oestrogen in women. They are used in the management of prostatic cancer, early or advanced breast cancer (suitable for hormonal manipulation) and for some benign gynaecological conditions such as endometriosis, fibroids and for pre thinning of the uterine endometrium. For paediatric patients at East Cheshire NHS Trust Zoladex® and Prostap® SR are used for the treatment of Precocious Puberty. This policy has been developed in response to the increase in medical and nursing staff receiving training to deliver both Zoladex® and Prostap® within the acute hospital setting or the community. It is not mandatory for any staff member to undertake administration of either medication but is encouraged in those who wish to increase their bank of clinical skills. The scope of the policy covers all children from birth up to 18 years of age in line with the East Cheshire NHS Trust Policy for the Admission of Children and Young People age 16 and over to the Children’s Ward (2008) Supersedes: New policy Description of Amendment(s): This policy will impact on: All paediatric trust staff Financial Implications: Policy Area: Women & Children’s
Document Reference:
Version Number: 1
Effective Date: February 2015
Issued By:
Review Date: Feb 2017
Authors: Malcolm Wallace (Charge Nurse)
Impact Assessment Date: Jan 2015
Consultation:
Approval Committee
APPROVAL RECORD Committees / Group CCNT team members, Children’s Ward Manager, Head of Children’s services, Paediatric Clinical lead, Paediatric Consultants responsible for Endocrine patients Women and Children’s SQS
Ratified by Committee/ Executive Director: Received for information:
Women and Children’s SQS
Date Nov 2014
Feb 2015 Feb 2015
2 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015
Contents 0.0 1.0
2.0
Introduction (pg 3) 1.1
Policy & Scope
1.2
Goserelin
1.3
Leuprorelin Acetate
Responsibilities (pg 3) 2.1
Chief Executive
2.2
Head of Children’s Services, Children’s Ward Manager & Clinical Lead
2.3
Children’s Community Nursing Team & Ward Sisters/Consultants
2.4
Clinical Staff
3.0
Principles (pg 4)
4.0
Authority to Proceed (pg 4)
5.0
Consent (pg 4)
6.0
Training/Skills (pg 4)
7.0
Contra-indications (pg 5)
8.0
7.1
Zoladex®
7.2
Prostap®
Side Effects (pg 5) 8.1
Zoladex®
8.2
Prostap®
9.0
Monitoring (pg 5)
10.0
References (pg 5)
11.0
Procedures (pg 5) 11.1
Procedure for Administration of Zoladex® 11.1.1 Equipment required 11.1.2 Prior to Administration 11.1.3 Procedure
11.2
Procedure for Administration of Prostap® 11.2.1 Equipment required 11.2.2 Prior to Administration 11.2.3 Procedure
12.0
Appendices (pg 8) 12.1 Competency tool for Administration of Zoladex® 12.2 Competency tool Administration of Prostap®
13.0
Equality Analysis (pg 11)
3 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015
1.0 Introduction 1.1 Policy & Scope Goserelin and Leuprorelin are types of hormone therapy drug called lutenizing hormone releasing hormone analogue (LHRHa). Goserelin is also known as Zoladex® and shall be referred to as such within this policy whilst Leuprorelin is also known as Prostap® SR DCS and will be referred to as such within this policy. Both work by interrupting the cycle of hormone production in the body, stopping production of testosterone in men and oestrogen in women. They are used in the management of prostatic cancer, early or advanced breast cancer (suitable for hormonal manipulation) and for some benign gynaecological conditions such as endometriosis, fibroids and for pre thinning of the uterine endometrium. For paediatric patients at East Cheshire NHS Trust Zoladex® and Prostap® SR are used for the treatment of Precocious Puberty. This policy has been developed in response to the increase in medical and nursing staff receiving training to deliver both Zoladex® and Prostap® within the acute hospital setting or the community. It is not mandatory for any staff member to undertake administration of either medication but is encouraged in those who wish to increase their bank of clinical skills. The scope of the policy covers all children from birth up to 18 years of age in line with the East Cheshire NHS Trust Policy for the Admission of Children and Young People age 16 and over to the Children’s Ward (2008) 1.2 Goserelin (Zoladex®) Zoladex® is designed for subcutaneous implantation which provides continuous release over a 12 week period. The implant is presented as a pre-filled syringe applicator containing Goserelin Acetate and is available in two doses; 3.6mg or 10.8mg. Once prescribed by a medical practitioner Zoladex® is injected subcutaneously into the patient’s thigh by a trained health professional. 1.3 Leuprorelin Acetate (Prostap® SR DCS) Prostap® SR DCS is designed for both subcutaneous or intra-muscular injection on a monthly basis. It is presented as a powder and solvent for prolonged-release suspension for injection in a prefilled syringe at a dose of 3.75mg or 11.25mg. 2.0 Responsibilities 2.1 Chief Executive The Trust Chief Executive has overall responsibility for the implementation of this policy and to ensure that proper training is in place so that medical and nursing staff can fulfil their duties in accordance with this policy. 2.2 Head of Children’s Services, Children’s Ward Manager & Clinical lead The Head of Children’s Services, Children’s Ward Manager and Clinical Lead has a responsibility for the operational implementation of this policy and associated procedures. They will ensure that the policy and training is made available to all doctors and nurses whose role it is to administer the injections. They will also monitor the implementation of a robust risk assessment approach to the administration of both Zoladex® and Prostap® SR DCS in the community and acute hospital setting through audit of clinical and non clinical records 2.3 Children’s Community Nursing Team & Ward Sisters/Consultants
4 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015
Children’s Community Nursing Team (CCNT) & Ward Sisters will ensure that all nursing staff wishing to deliver Zoladex® and Prostap® SR DCS have sufficient training to do so and have been signed off as competent. There is a named Paediatric Consultant with Endocrine specialism who will oversee and provide this training and maintain responsibility for the patients affected by this policy. The named Consultant can alter the frequency of injections based on clinical/pubertal changes and biochemical levels. 2.4 Clinical Staff All healthcare professionals are responsible for their own actions and must exercise their own personal judgement at all times. Any clinical decision to deviate from this policy and associated procedures must be clearly documented in the medical and/or nursing records for the patient including the reason for variance and any subsequent action taken. All clinical staff have a duty to take all reasonable measures to take care of their own and the patient’s safety whilst administering Zoladex® and Prostap® SR DCS.
3.0 Principles 3.1 Principles of Health and Safety relating to storage, administration and disposal of medications will be adhered to with reference to appropriate organisational policies. 3.2 Principles relating to prevention of cross infection will underpin practice with reference to appropriate organisational policies. 3.3 Principles relating to consent should be considered alongside this policy with reference to appropriate organisational and national policies. 3.4 Patients should be encouraged to have choice in whether their injection is given in the community or in the acute hospital setting.
4.0 Authority to Proceed 4.1 Treatment should be prescribed by a medical practitioner/ 4.2 Authorisation from the patient’s consultant must be obtained prior to the procedure being performed. 4.3 Treatment should only be given by trained clinical staff that are competent to proceed. 5.0 Consent 5.1 Patient/parental consent should be obtained prior to administration of either injection. Although some older children may have the capacity to grant or refuse consent for the treatment younger children may rely solely on the capacity of his/her parents to act in his/her best interest. The patient/parent must be given all the information required to make an informed decision. A young person who is deemed to have capacity to consent for themselves must be listened to. 6.0 Training/Skills
5 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015
6.1 No formal training exists at East Cheshire NHS Trust for the administration of Zoladex® and Prostap® SR DCS. 6.2 Any staff wishing to administer Zoladex® and/or Prostap® SR DCS must receive initial training by Endocrine Specialist Paediatric Consultant, or attend an authorised study day at an alternative trust. 6.3 Any staff wishing to administer Zoladex® and Prostap® SR DCS must complete a self assessment and then be supervised on three occasions before being seemed competent to administer the injections unsupervised. 6.4 All staff who have received training in the administration of Zoladex® and Prostap® SR DCS must complete yearly competency forms as part of the trust appraisal process. 7.0 Contra-indications 7.1 Zoladex® Zoladex® should not be given to patients with a known hypersensitivity to the active substance or exipients of Zoladex® Zoladex® is contra-indicated with known or suspected pregnancy and lactation and undiagnosed vaginal bleeding. 7.2 Prostap® SR DCS
Prostap® SR DCS should not be given to patients with a known hypersensitivity to the active substance or exipients of Prostap® Prostap® SR DCS is contra-indicated in women who are or may become pregnant whilst receiving the drug. Prostap® SR DCS should not be used in women who are breastfeeding or undiagnosed abnormal vaginal bleeding.
8.0 Side Effects 8.1 Zoladex®
Hypersensitivity reactions, hot flushes, sweating, sexual dysfunction, vaginal dryness, Gynaecomstia or changes in breast size, headaches, Gastro-intestinal disturbances, sleep disturbances, mood changes, Mild vaginal bleed (especially after the first dose). See manufacturer information for detailed side effects.
8.2 Prostap® SR DCS
In children: Emotional lability, headache, abdominal pain/cramps, nausea, vomiting, allergic reaction (rare). See manufacturer information for detailed side effects.
9.0 Monitoring 9.1 This Policy will be reviewed on a three yearly basis by the author/Practice Development Nurse/Ward Sister as appropriate in conjunction with the Paediatric Consultant responsible for Endocrine patients. 9.2 Any changes required will be made along with amendments to the competency forms and trained staff will be required to complete new competencies.
6 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015
10.0
11.0
References NHS Walsall Community Health Administration of Goserelin Implant (Zoladex) Clinical Procedure Policy (2009) Takeda (UK) Ltd Prostap*SRDCS Health Professionals User Leaflet (2012) AstraZeneca Information leaflet: Zoladex 3.6mg Implant (2014) AstraZeneca Information leaflet: Zoladex LA 10.8mg Implant (2014)
Procedures 11.1
Procedure for Administration of Zoladex® 11.1.1 Equipment required Correct prescription Apron Dressing Towel Gauze Swabs Drug Sharps bin Sterile plaster Disposal bag 11.1.2 Prior to Administration 1 hour prior to administration, the patient or carer may wish to apply a layer of Ametop Cream (1-5 hours prior if using EMLA cream) to the injection site. The cream should be covered with an occlusive dressing. 11.1.3 Procedure 1. Read patient notes & ensure correct prescription is available. 2. Explain procedure and possible side effects to patient and gain verbal consent to proceed. 3. Ensure patient is in comfortable position and upper body is slightly raised. 4. Wash hands and put on protective apron. 5. Prepare equipment onto clean dressing towel. 6. Remove occlusive dressing and wipe away Ametop/EMLA cream with gauze swabs (if required) 7. Wash Hands 8. Open foil packaging as directed and remove the syringe. 9. Check that the depot is visible in the window of the syringe. Do not try and remove air as this is not a liquid injection. 10. Remove the plastic safety tab away from the syringe and discard. 11. Remove needle cover. 12. Hold the syringe around the barrel using Aseptic Non Touch Technique; pinch the skin around the injection site. 13. With the bevel of the needle facing upwards, insert the needle at a 30-45 degree angle to the skin in one continuous deliberate motion until the protective sleeve touches the patient’s skin. 14. Administer the Zoladex® implant by depressing the plunger until you can depress it no further, activating the protective shield. You may hear a click and you will feel the protective shield automatically begin to slide and cover the needle.
7 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015
15. Withdraw the syringe and allow the protective shield to slide and cover the needle. 16. Dispose of the syringe in a sharps box. 17. Cover the injection site with a sterile non adherent dressing. 18. Dispose of remaining rubbish is disposal bag. 19. Record the injection in the patient record, noting drug dosage, batch number, expiry date and injection site. 20. Arrange next appointment for patient. 11.2
Procedure for Administration of Prostap® SR DCS 11.2.1 Equipment required Correct prescription Apron Dressing Towel Gauze Swabs Drug Sharps bin Sterile plaster Disposal bag 11.2.2 Prior to Administration 1 hour prior to administration, the patient or carer may wish to apply a layer of Ametop Cream (1-5 hours prior if using EMLA cream) to the injection site. The cream should be covered with an occlusive dressing. 11.2.3 Procedure 1. Read patient notes & ensure correct prescription is available. 2. Explain procedure and possible side effects to patient and gain verbal consent to proceed. 3. Ensure patient is in comfortable position and upper body is slightly raised. 4. Wash hands and put on protective apron. 5. Prepare equipment onto clean dressing towel. 6. Remove occlusive dressing and wipe away Ametop/EMLA cream with gauze swabs (if required) 7. Wash Hands 8. Remove administration device from packaging. 9. Screw the plunger rod into the end stopper until the stopper begins to turn. 10. Check that the needle is tight by twisting the needle cap clockwise. Do not over tighten. 11. Holding the syringe upright, release the dilutents by slowly pushing the plunger until the middle stopper is at the blue line in the middle of the barrel. 12. Gently tap the syringe on the palm keeping the syringe upright to thoroughly mix the particles to form a uniform suspension. The suspension will appear milky. 13. Remove the needle cap and advance the plunger to expel the air from the syringe. 14. At the time of the injection check the direction of the safety device (round mark should face upwards) and inject the entire contents of the syringe subcutaneously or intramuscularly. 15. Withdraw the needle from the patient and immediately activate the safety device by pushing the arrow forward with the thumb or finger until the device is fully extended and a click is heard or felt. 16. Dispose of the syringe in a sharps box. 17. Cover the injection site with a sterile non adherent dressing.
8 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015
18. Dispose of remaining rubbish is disposal bag. 19. Record the injection in the patient record, noting drug dosage, batch number, expiry date and injection site. 20. Arrange next appointment for patient.
9 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015
Appendices
10 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015
Administration of Zoladex® Name:
Document competency stage (1-5) and sign st
Benner's Stages: Stage 1 – Novice Stage 3 – Competent
Stage 2 – Advanced Beginning Stage 4 – Proficient Stage 5 – Expert
N.B. Minimum stage 3 competent should be achieved, where this is not the case please complete action plan to achieve stage 3 Standard - All staff should be at level 3 Collect appropriate equipment Read patient notes & ensure correct prescription is available. Explain procedure and possible side effects to patient and gain verbal consent to proceed Ensure patient is in comfortable position and upper body is slightly raised. Wash hands and put on protective apron. Prepare equipment onto clean dressing towel Remove occlusive dressing and wipe away Ametop/EMLA cream with gauze swabs (if required) Wash Hands Open foil packaging as directed and remove the syringe. Check that the depot is visible in the window of the syringe. Do not try and remove air as this is not a liquid injection. Remove the plastic safety tab away from the syringe and discard. Remove needle cover. Hold the syringe around the barrel using Aseptic Non Touch Technique; pinch the skin around the injection site. With the bevel of the needle facing upwards, insert the needle at a 30-45 degree angle to the skin in one continuous deliberate motion until the protective sleeve touches the patient’s skin. Administer the Zoladex® implant by depressing the plunger until you can depress it no further, activating the protective shield. You may hear a click and you will feel the protective shield automatically begin to slide and cover the needle. Withdraw the syringe and allow the protective shield to slide and cover the needle. Dispose of the syringe in a sharps box. Cover the injection site with a sterile non adherent dressing.
nd
SelfAssessment
1 Assessment Stage
2 Assessment Stage
Final sign off by Assessor
Variance Actions
Date/initial
Date/initial
Date/initial
Date/initial
Date/initial
11 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015
Dispose of remaining rubbish is disposal bag. Record the injection in the patient record, noting drug dosage, batch number, expiry date and injection site. Administration of Prostap® SR DCS Name:
Document competency stage (1-5) and sign st
Benner's Stages: Stage 1 – Novice Stage 3 – Competent
Stage 2 – Advanced Beginning Stage 4 – Proficient Stage 5 – Expert
N.B. Minimum stage 3 competent should be achieved, where this is not the case please complete action plan to achieve stage 3 Standard - All staff should be at level 3 Collect appropriate equipment Read patient notes & ensure correct prescription is available. Explain procedure and possible side effects to patient and gain verbal consent to proceed Ensure patient is in comfortable position and upper body is slightly raised. Wash hands and put on protective apron. Prepare equipment onto clean dressing towel Remove occlusive dressing and wipe away Ametop/EMLA cream with gauze swabs (if required) Wash Hands Remove administration device from packaging Screw the plunger rod into the end stopper until the stopper begins to turn. Check that the needle is tight by twisting the needle cap clockwise. Do not over tighten. Holding the syringe upright, release the dilutents by slowly pushing the plunger until the middle stopper is at the blue line in the middle of the barrel. Gently tap the syringe on the palm keeping the syringe upright to thoroughly mix the particles to form a uniform suspension. The suspension will appear milky. Remove the needle cap and advance the plunger to expel the air from the syringe. At the time of the injection check the direction of the safety device (round mark should face upwards) and inject the entire contents of the syringe subcutaneously or intramuscularly Withdraw the needle from the patient and immediately activate the safety device by pushing the arrow forward with the thumb or finger until the device is fully extended and
nd
SelfAssessment
1 Assessment Stage
2 Assessment Stage
Final sign off by Assessor
Variance Actions
Date/initial
Date/initial
Date/initial
Date/initial
Date/initial
12 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015
a click is heard or felt. Dispose of the syringe in a sharps box. Cover the injection site with a sterile non adherent dressing. Dispose of remaining rubbish is disposal bag. Record the injection in the patient record, noting drug dosage, batch number, expiry date and injection site.
13 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015
12.0
Equality Analysis
Equality Analysis (Impact assessment) Please START this assessment BEFORE writing your policy, procedure, proposal, strategy or service so that you can identify any adverse impacts and include action to mitigate these in your finished policy, procedure, proposal, strategy or service. Use it to help you develop fair and equal services. Eg. If there is an impact on Deaf people, then include in the policy how Deaf people will have equal access.
1. What is being assessed? Children’s Ward & Children’s Community Nursing Team: Administration of Goserelin Implant (Zoladex®) and Leuprorelin Acetate Depot Injection (Prostap® SR DCS) Clinical Procedure Policy
Details of person responsible for completing the assessment:
Name: Malcolm Wallace Job Title: Charge Nurse Team: Children’s Unit
State main purpose or aim of the policy, procedure, proposal, strategy or service: (usually the first paragraph of what you are writing. Also include details of legislation, guidance, regulations etc which have shaped or informed the document) Goserelin and Leuprorelin are types of hormone therapy drug called lutenizing hormone releasing hormone analogue (LHRHa). Goserelin is also known as Zoladex® and shall be referred to as such within this policy whilst Leuprorelin is also known as Prostap® and will be referred to as such within this policy. Both work by interrupting the cycle of hormone production in the body, stopping production of testosterone in men and oestrogen in women. They are used in the management of prostatic cancer, early or advanced breast cancer (suitable for hormonal manipulation) and for some benign gynaecological conditions such as endometriosis, fibroids and for pre thinning of the uterine endometrium. For paediatric patients at East Cheshire NHS Trust Zoladex® and Prostap® SR are used for the treatment of Precocious Puberty. This policy has been developed in response to the increase in medical and nursing staff receiving training to deliver both Zoladex® and Prostap® within the acute hospital setting or the community. It is not mandatory for any staff member to undertake administration of either medication but is encouraged in those who wish to increase their bank of clinical skills. The scope of the policy covers all children from birth up to 18 years of age in line with the East Cheshire NHS Trust Policy for the Admission of Children and Young People age 16 and over to the Children’s Ward (2008)
2. Consideration of Data and Research To carry out the equality analysis you will need to consider information about the people who use the service and the staff that provide it. Think about the information below – how does this apply to your policy, procedure, proposal, strategy or service 2.1 Give details of RELEVANT information available that gives you an understanding of who will be affected by this document Cheshire East (CE) covers Eastern Cheshire CCG and South Cheshire CCG. Cheshire West & Chester (CWAC) covers Vale Royal CCG and Cheshire West CCG. In 2011, 370,100 people resided in CE and 329,608 people resided in CWAC. 14 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015
Age: East Cheshire and South Cheshire CCG’s serve a predominantly older population than the national average, with 19.3% aged over 65 (71,400 people) and 2.6% aged over 85 (9,700 people). Vale Royal CCGs registered population in general has a younger age profile compared to the CWAC average, with 14% aged over 65 (14,561 people) and 2% aged over 85 (2,111 people). Since the 2001 census the number of over 65s has increased by 26% compared with 20% nationally. The number of over 85s has increased by 35% compared with 24% nationally. Race: In 2011, 93.6% of CE residents, and 94.7% of CWAC residents were White British 5.1% of CE residents, and 4.9% of CWAC residents were born outside the UK – Poland and India being the most common 3% of CE households have members for whom English is not the main language (11,103 people) and 1.2% of CWAC households have no people for whom English is their main language. Gypsies & travellers – estimated 18,600 in England in 2011. Gender: In 2011, c. 49% of the population in both CE and CWAC were male and 51% female. For CE, the assumption from national figures is that 20 per 100,000 are likely to be transgender and for CWAC 1,500 transgender people will be living in the CWAC area. Disability: In 2011, 7.9% of the population in CE and 8.7% in CWAC had a long term health problem or disability In CE, there are c.4500 people aged 65+ with dementia, and c.1430 aged 65+ with dementia in CWAC. 1 in 20 people over 65 has a form of dementia Over 10 million (c. 1 in 6) people in the UK have a degree of hearing impairment or deafness. C. 2 million people in the UK have visual impairment, of these around 365,000 are registered as blind or partially sighted. In CE, it is estimated that around 7000 people have learning disabilities and 6500 people in CWAC. Mental health – 1 in 4 will have mental health problems at some time in their lives. Sexual Orientation: CE - In 2011, the lesbian, gay, bisexual and transgender (LGBT) population in CE was estimated at18,700, based on assumptions that 5-7% of the population are likely to be lesbian, gay or bisexual and 20 per 100,000 are likely to be transgender (The Lesbian & Gay Foundation). CWAC - In 2011, the LGBT population in CWAC is unknown, but in 2010 there were c. 20,000 LGB people in the area and as many as 1,500 transgender people residing in CWAC. Religion/Belief: The proportion of CE people classing themselves as Christian has fallen from 80.3% in 2001 to 68.9% In 2011 and in CWAC a similar picture from 80.7% to 70.1%, the proportion saying they had no religion doubled in both areas from around 11%-22%. Christian: 68.9% of Cheshire East and 70.1% of Cheshire West & Chester Sikh: 0.07% of Cheshire East and 0.1% of Cheshire West & Chester Buddhist: 0.24% of Cheshire East and 0.2% of Cheshire West & Chester Hindu: 0.36% of Cheshire East and 0.2% of Cheshire West & Chester Jewish: 0.16% of Cheshire East and 0.1% of Cheshire West & Chester 15 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015
Muslim: 0.66% of Cheshire East and 0.5% of Cheshire West & Chester Other: 0.29% of Cheshire East and 0.3% of Cheshire West & Chester None: 22.69%of Cheshire East and 22.0% of Cheshire West & Chester Not stated: 6.66% of Cheshire East and 6.5% of Cheshire West & Chester
Carers: In 2011, nearly 11% (40,000) of the population in CE are unpaid carers and just over 11% (37,000) of the population in CWAC.
2.2 Evidence of complaints on grounds of discrimination: (Are there any complaints or concerns raised either from patients or staff (grievance) relating to the policy, procedure, proposal, strategy or service or its effects on different groups?) Nil 2.3 Does the information gathered from 2.1 – 2.3 indicate any negative impact as a result of this document? Nil
3. Assessment of Impact Now that you have looked at the purpose, etc. of the policy, procedure, proposal, strategy or service (part 1) and looked at the data and research you have (part 2), this section asks you to assess the impact of the policy, procedure, proposal, strategy or service on each of the strands listed below. RACE: From the evidence available does the policy, procedure, proposal, strategy or service affect, or have the potential to affect, racial groups differently? Yes No X Explain your response: This policy is to cover paediatric patients receiving Zoladex® and Prostap® SR. All patients will be considered for the treatment regardless of race. If a patient or carer’s first language is not English, staff will follow the trust interpretation policy.
___________________________________________________________________________ GENDER (INCLUDING TRANSGENDER): From the evidence available does the policy, procedure, proposal, strategy or service affect, or have the potential to affect, different gender groups differently? Yes No X Explain your response: This policy is to cover paediatric patients receiving Zoladex® and Prostap® SR. All patients will be considered for the treatment regardless of gender
DISABILITY From the evidence available does the policy, procedure, proposal, strategy or service affect, or have the potential to affect, disabled people differently? Yes No X Explain your response: 16 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015
This policy is to cover paediatric patients receiving Zoladex® and Prostap® SR. All patients will be considered for the treatment regardless of disability.
___________________________________________________________________________ AGE: From the evidence available does the policy, procedure, proposal, strategy or service, affect, or have the potential to affect, age groups differently? Yes No X Explain your response: This policy is to cover paediatric patients receiving Zoladex® and Prostap® SR. All patients will be considered for the treatment regardless of age.
LESBIAN, GAY, BISEXUAL: From the evidence available does the policy, procedure, proposal, strategy or service affect, or have the potential to affect, lesbian, gay or bisexual groups differently? Yes No X Explain your response: This policy is to cover paediatric patients receiving Zoladex® and Prostap® SR. All patients will be considered for the treatment regardless of sexual orientation.
___________________________________________________________________________ RELIGION/BELIEF: From the evidence available does the policy, procedure, proposal, strategy or service affect, or have the potential to affect, religious belief groups differently? Yes No X Explain your response: This policy is to cover paediatric patients receiving Zoladex® and Prostap® SR. All patients will be considered for the treatment regardless of religion/belief. For patients of different cultures and beliefs, staff will check the content of the drug and discuss this with the patient and carer if a conflict is identified, eg porcine products and Muslim patients.
___________________________________________________________________________ CARERS: From the evidence available does the policy, procedure, proposal, strategy or service affect, or have the potential to affect, carers differently? Yes No X Explain your response: This policy is to cover paediatric patients receiving Zoladex® and Prostap® SR. All patients will be considered for the treatment and carers involved in information and explanation as appropriate to support the patient.
___________________________________________________________________________ OTHER: EG Pregnant women, people in civil partnerships, human rights issues. From the evidence available does the policy, procedure, proposal, strategy or service affect, or have the potential to affect any other groups differently? Yes No X Explain your response: No patient will be discriminated against on any grounds.
___________________________________________________________________________
4. Safeguarding Assessment - CHILDREN a. Is there a direct or indirect impact upon children? Yes X No b. If yes please describe the nature and level of the impact (consideration to be given to all 17 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015
children; children in a specific group or area, or individual children. As well as consideration of impact now or in the future; competing / conflicting impact between different groups of children and young people: These guidelines are designed to be used for all young people up to age 18 and will therefore impact on all these children.
c. If no please describe why there is considered to be no impact / significant impact on children
5. Relevant consultation Having identified key groups, how have you consulted with them to find out their views and that the made sure that the policy, procedure, proposal, strategy or service will affect them in the way that you intend? Have you spoken to staff groups, charities, national organisations etc? Groups identified for consultation: Community Service Managers Children’s Services Manager Children’s Ward Matron Children’s Community Nursing Team Children’s Ward Sisters Paediatric Consultants
6. Date completed:
Review Date:
7. Any actions identified: Have you identified any work which you will need to do in the future to ensure that the document has no adverse impact? Action Lead Date to be Achieved
8. Approval – At this point, you should forward the template to the Trust Equality and Diversity
Lead
[email protected]
Approved by Trust Equality and Diversity Lead: Date: 17.3.15
18 Paediatric Zoladex & Prostap Policy v1 Malcolm Wallace Feb 2015